FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	VAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MAHONEY DAVID L								2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]									oplicable) ector	ng Perso	Person(s) to Issuer 10% Owner		
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS						3. Date of Earliest Transaction (Month/Day/Year) 02/17/2006										bel	cer (give title ow)	Other (s below)			
149 COMMONWEALTH DRIVE							4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) MENLO	Street) MENLO PARK CA 94025					,										X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day							Execution Date,			Transaction Disposed Code (Instr.			ies Acquired (A) o Of (D) (Instr. 3, 4			nd 5) Secu Bend	nount of irities ificially ed Following	6. Own Form: I (D) or I (I) (Inst	Direct ndirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	Amount	(A) or (D) Prid		Price	Tran	Transaction(s) (Instr. 3 and 4)			(111501. 4)					
Common Stock 02/17/2							2006			P		10,700		A	\$5.0	741	40,700		[By trust	
Common Stock 02/21/2							2006					10,000) .	A \$4.98		89 50,700			[By trust	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversi or Exerci Price of Derivativ Security	on se	Transaction ate lonth/Day/Year)	3A. Deem Execution if any (Month/D	n Date,		Transaction Code (Instr.		n of		Exerci on Da Day/Yo		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Own For Dire or I	nership m: ect (D) ndirect Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Nui of	ount mber ares						

Explanation of Responses:

Remarks:

/s/ Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

02/22/2006

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.